BerandaCGEN • NASDAQ
add
Compugen Ltd
$2,36
Setelah Jam Perdagangan Normal:(0,85%)+0,020
$2,38
Tutup: 16 Jan, 18.22.22 GMT-5 · USD · NASDAQ · Pernyataan Penyangkalan
Tutup sebelumnya
$2,11
Rentang hari
$2,11 - $2,38
Rentang tahun
$1,13 - $2,66
Kapitalisasi pasar
220,74Â jt USD
Volume Rata-Rata
545,80Â rb
Rasio P/E
-
Hasil dividen
-
Bursa utama
NASDAQ
Berita pasar
Keuangan
Laporan Laba Rugi
Pendapatan
Penghasilan bersih
| (USD) | Sep 2025info | Perubahan Y/Y |
|---|---|---|
Pendapatan | 1,89Â jt | -88,96% |
Biaya operasional | 8,13Â jt | -9,97% |
Penghasilan bersih | -6,98Â jt | -646,94% |
Margin laba bersih | -369,06 | -5.053,83% |
Penghasilan per saham | -0,07 | -800,00% |
EBITDA | -7,77Â jt | -268,40% |
Tarif pajak efektif | -0,58% | — |
Neraca
Total aset
Total liabilitas
| (USD) | Sep 2025info | Perubahan Y/Y |
|---|---|---|
Investasi tunai jangka pdk | 86,09Â jt | -23,62% |
Total aset | 97,84Â jt | -20,78% |
Total liabilitas | 54,02Â jt | -14,29% |
Total ekuitas | 43,83 jt | — |
Saham yang beredar | 93,54 jt | — |
Harga terhadap nilai buku | 4,49 | — |
Tingkat pengembalian aset | -19,31% | — |
Tingkat pengembalian modal | -39,47% | — |
Arus Kas
Perubahan kas bersih
| (USD) | Sep 2025info | Perubahan Y/Y |
|---|---|---|
Penghasilan bersih | -6,98Â jt | -646,94% |
Kas dari operasi | — | — |
Kas dari investasi | — | — |
Kas dari pembiayaan | — | — |
Perubahan kas bersih | — | — |
Arus kas bebas | — | — |
Tentang
Compugen Ltd. is a clinical-stage publicly traded predictive drug discovery and development company headquartered in Israel, with shares traded on the NASDAQ Capital Market and on the Tel Aviv Stock Exchange. Compugen was established as computational drug discovery service provider in 1993. Compugen originally acted as service provider for pharma companies, supplying its software and computational services to predict different types of biological phenomena. It had arrangements with big companies such as Novartis AG, Abbot Laboratories and Pfizer Inc. Subsequently, Compugen made a decision to become a drug development company with its own internal pipeline, and in 2010, decided to a focus on oncology and immunology. OncoMed Pharmaceuticals and Five Prime Therapeutics are among Compugen's competitors. Wikipedia
Didirikan
10 Feb 1993
Situs
Karyawan
74
